Simulations Plus, Inc. (NASDAQ:SLP – Get Free Report) has been assigned an average recommendation of “Reduce” from the six brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and five have given a hold recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $17.25.
A number of equities analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Simulations Plus in a research note on Tuesday, October 6th. BTIG Research dropped coverage on Simulations Plus in a research report on Wednesday, October 7th. They set a “neutral” rating on the stock.
View Our Latest Stock Analysis on Simulations Plus
Simulations Plus Stock Performance
Shares of SLP opened at $18.50 on Friday. The stock’s 50-day moving average price is $18.48 and its two-hundred day moving average price is $16.27. Simulations Plus has a 12 month low of $11.09 and a 12 month high of $21.01. The company has a market capitalization of $374.16 million, a PE ratio of 46.25 and a beta of 1.31.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. First Light Asset Management LLC raised its holdings in shares of Simulations Plus by 6.1% during the second quarter. First Light Asset Management LLC now owns 2,792,677 shares of the technology company’s stock valued at $51,134,000 after purchasing an additional 159,854 shares during the period. BlackRock Inc. bought a new position in shares of Simulations Plus in the 2nd quarter worth $27,503,000. Gabelli Funds LLC lifted its holdings in shares of Simulations Plus by 95.5% in the 3rd quarter. Gabelli Funds LLC now owns 287,445 shares of the technology company’s stock worth $5,298,000 after purchasing an additional 140,387 shares in the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. grew its position in Simulations Plus by 94.2% in the 3rd quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 231,423 shares of the technology company’s stock valued at $4,265,000 after purchasing an additional 112,273 shares during the period. Finally, Glazer Capital LLC acquired a new stake in Simulations Plus in the 2nd quarter valued at $3,691,000. 78.08% of the stock is owned by institutional investors.
About Simulations Plus
Simulations Plus, Inc. develops software and provides consulting services for the pharmaceutical and biotechnology industries. Its tools help researchers model how drugs behave in the body, assess drug properties, and support decisions during drug discovery and development. The company’s products include GastroPlus for physiologically based pharmacokinetic modeling and simulation, ADMET Predictor for estimating absorption, distribution, metabolism, excretion and toxicity properties, and MonolixSuite for pharmacometrics and quantitative pharmacology.
Featured Stories
- Five stocks we like better than Simulations Plus
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.
